| 摘要: |
| 目的 探讨弥漫性大B细胞淋巴瘤(DLBCL)中遍在蛋白活化酶E1(UBE1)和凋亡抑制基因Bcl-2蛋白的表达及临床病理意义。 方法 收集80例DLBCL组织和30例良性淋巴组织反应性增生(RH),应用免疫组化技术(EnVision二步法)对DLBCL组织进行免疫分型并检测其免疫表型GCB型、ABC型中UBE1、Bcl-2蛋白的表达; 同时检测UBE1、Bcl-2蛋白在RH组织中的表达。分析UBE1、Bcl-2蛋白表达与DLBCL患者临床病理特征的关系,及DLBCL组织中UBE1与Bcl-2表达的相关性。 结果 DLBCL组织中UBE1阳性表达率为65.0%(52/80),RH组织中阳性表达率为13.3%(4/30),两者差异具有统计学意义(P<0.05);GCB型和ABC型的阳性表达率分别为53.3%(16/30)、72.0%(36/50),两者差异具有统计学意义(P<0.05)。DLBCL组织中Bcl-2阳性表达率为51.3%(41/80),RH组织中阳性表达率为10.0%(3/30),两者差异具有统计学意义(P<0.05);GCB型和ABC型的阳性表达率分别为36.7%(11/30)、60.0%(30/50),两者差异具有统计学意义(P<0.05)。在DLBCL组织中,UBE1的阳性表达率与患者的年龄、累及结外数目有关(P<0.05); Bcl-2的阳性表达率与DLBCL患者的年龄、Ann Arbor分期、累及结外数目、国际预后指数等病理特征有关(P<0.05)。UBE1在ABC型中的表达与Bcl-2的表达呈正相关(r=0.582, P=0.001)。结论 UBE1、Bcl-2蛋白在DLBCL的ABC型中表达较高,在肿瘤的发生、发展及侵袭中起着一定的作用,UBE1与Bcl-2蛋白的高表达可能提示DLBCL患者的不良预后。 |
| 关键词: 遍在蛋白活化酶E1 Bcl-2 弥漫性大B细胞淋巴瘤 |
| DOI：10.3724/SP.J.1008.2013.00295 |
| 投稿时间：2012-12-25修订日期：2013-02-20 |
| 基金项目:安徽省教育厅自然科学研究基金(KJ2013B322). |
|
| Expression of UBE1 and Bcl-2 in diffuse large B cell lymphoma and its clinical significance |
| CHEN Bing1*,SU Zu-lan2 |
(1. Department of Pathology, Wannan Medical College, Wuhu 241001, Anhui, China
2. Department of Pathology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong, China
*Corresponding author.) |
| Abstract: |
| Objective To study the expression of ubiquitin-activating enzyme E1 (UBE1) and Bcl-2 in diffuse large B cell lymphoma (DLBCL) and its clinicopathological relevance. Methods Tumor tissues were collected from 80 DLBCL patients, and tissues from 30 patients with reactive lymphoid hyperplasia (RH) were taken as controls. Immunohistochemistry detection (EnVision method) was used to detect the expressions of CD10, Bcl-6 and MUM1 in DLBCL tissues for immunology typing of GCB or ABC. The expression of UBE1 and Bcl-2 proteins in DLBCL tissues and RH tissues was assayed by immunohistochemical staining, and its correlation with patients’ clinical pathological indices were analyzed. We also analyzed the correlation of UBE1 expression with Bcl-2 expression in DLBCL tissues. Results The positive rates of UBE1 were 65.0% (52/80) in DLBCL tissues and 13.3%(4/30) in RH tissues (P<0.05). The positive rates of UBE1 were 53.3% (16/30) for GCB type DLBCL and 72.0%(36/50) for ABC type (P<0.05). The positive rates of Bcl-2 were 51.3% (41/80) in DLBCL tissues and 10.0% (3/30) in RH tissues (P<0.05). The positive rates of Bcl-2 were 36.7%(11/30) for GCB type DLBCL and 60.0% (30/50) for ABC type (P<0.05). The positive rate of UBE1 was correlated with age and the extranodal involvement site (P<0.05). The positive rate of Bcl-2 was correlated with age, Ann Arbor stage, extranodal involvement site and international prognostic index (P<0.05). UBE1 expression was positively correlated with Bcl-2 in ABC type DLBCL (r=0.582, P=0.001). Conclusion UBE1 and Bcl-2 proteins are highly expressed in ABC type DLBCL tissues, which probably plays a role in the development and progression of DLBCL. High expression of UBE1 and Bcl-2 may indicate poor prognosis of DLBCL patients. |
| Key words: ubiquitin-activating enzyme E1 Bcl-2 protein diffusse large B-cell lymphoma |
